The RPL13 antibody is a crucial tool in studying ribosomal protein L13 (RPL13), a component of the 60S ribosomal subunit involved in protein synthesis. RPL13 plays roles beyond translation, including regulating inflammatory responses, apoptosis, and cell cycle progression. It is implicated in stress-induced ribosome remodeling, where it may participate in specialized translational control under conditions like nutrient deprivation or viral infection. Researchers use RPL13 antibodies in techniques such as Western blotting, immunofluorescence, and immunohistochemistry to assess protein expression, localization, and interactions. Dysregulation of RPL13 has been linked to cancers (e.g., colorectal, breast), autoimmune disorders, and metabolic diseases, making its antibody valuable for diagnostic or mechanistic studies. Specificity validation via knockout/knockdown controls is critical due to potential cross-reactivity with other ribosomal proteins. Commercial RPL13 antibodies are typically raised against conserved epitopes, allowing cross-species reactivity (human, mouse, rat). Recent studies also explore RPL13's moonlighting functions in extracellular signaling and its role in ribosomopathies, highlighting the antibody's utility in diverse biomedical research contexts.